Trials / Recruiting
RecruitingNCT05803785
Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
A Phase 1, Open Label, Ascending Dose Study to Evaluate the Safety of BBC1501 Administered by Intravitreal Injection for Neovascular Age-Related Macular Degeneration (nAMD)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Benobio Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This open-label study is being conducted to evaluate the initial safety and tolerability of BBC1501 IVT in patients with nAMD. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of IVT BBC1501 in patients with nAMD. The secondary objective of this study is to exploratory of BBC1501 efficacy following 3 ascending dose of BBC1501 in nAMD patient.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BBC1501 | BBC1501 solution for Intravitreal injection |
Timeline
- Start date
- 2024-10-31
- Primary completion
- 2025-12-01
- Completion
- 2026-03-01
- First posted
- 2023-04-07
- Last updated
- 2025-07-08
Locations
2 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT05803785. Inclusion in this directory is not an endorsement.